Subjective Outcome
5 compoundsin Regimen’s catalog are configured to track appetite via Rate Today. Each one shows the dose range, listed benefits, and every outcome it’s set up to monitor. Tap through to plan a dose with the free reconstitution calculator.
Appetite is regulated by a network of hormones — ghrelin (hunger), leptin (satiety), GLP-1, PYY, and CCK (post-meal satiety) — that converge on the hypothalamic arcuate nucleus. GLP-1 receptor agonists work by amplifying the satiety arm: they bind to GLP-1 receptors in the brain, slow gastric emptying, and reduce reward-driven eating by acting on dopaminergic pathways in the ventral tegmental area.
The clinical effect is large. In STEP 1, semaglutide reduced ad libitum caloric intake at a buffet meal by roughly 24% versus placebo. Users typically describe it as a quieting of food noise rather than nausea-driven aversion. Cagrilintide (an amylin analog) and the tirzepatide GIP/GLP-1 dual action add additional appetite-modulating pathways.
For people who want appetite suppression without the GI side-effect profile of injectable GLP-1s, oral GLP-1s (Rybelsus) and lower-dose titration protocols offer alternatives. Older anorectic peptides (MOTS-c, AOD-9604) have weaker effect sizes and are typically adjunctive rather than primary.
Anchor citation: Friedrichsen M et al.. Effect of Semaglutide on Appetite, Energy Intake, and Eating Behavior. Diabetes, Obesity and Metabolism, 2021.
5 compounds
GLP-1 Receptor Agonist
A once-weekly GLP-1 receptor agonist for weight management and metabolic health.
Tracks
GIP / GLP-1 Dual Agonist
A once-weekly dual GIP and GLP-1 receptor agonist delivering superior weight loss and metabolic improvements compared to GLP-1 monotherapy.
Tracks
GLP-1 Receptor Agonist (Saxenda / Victoza)
Daily injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza, up to 1.8 mg/day) and chronic weight management (Saxenda, up to 3.0 mg/day). Slows gastric emptying, increases satiety, improves glycemic control, and reduces cardiovascular events in T2D.
Tracks
GIP / GLP-1 / Glucagon Triple Agonist
Tracks
Long-Acting Amylin Analog
Tracks
Tirzepatide produces the largest reduction in self-reported hunger scores in head-to-head trials, followed by semaglutide and liraglutide. Cagrilintide is added to semaglutide in the CagriSema combination to extend the satiety effect. Retatrutide, currently in phase 3, shows the strongest early signal but is not yet approved.
Semaglutide and tirzepatide both have half-lives near a week (semaglutide ~165 hours; tirzepatide ~120 hours), which is why they are dosed once weekly. Steady-state levels are reached after 4–5 weeks. Most users notice a gradual day-to-day rise in hunger toward the end of the week between doses 1–3, which smooths out once steady state is reached.
Yes. Discontinuation studies (STEP 4, STEP 1 follow-up) show that hunger and caloric intake return to baseline within months of stopping, and most of the weight regains within a year unless the protocol is replaced with structural lifestyle change. Maintenance dosing — a lower dose continued long-term — is the standard mitigation.
Related reading
Best peptide tracker app in 2026
An honest multi-protocol comparison of Regimen, PeptIQ, Shotsy, MeAgain, and the GLP-1 calculator apps.
Other outcomes